SCHEMBL16610534

SCHEMBL16610534

COc1c(O)nc(N2CCC[C@H]2c2ccc(C)cc2)nc1O

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.39
MAOA P21397 2/20 0.39
MAOB P27338 2/20 0.39
ROCK2 O75116 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
PROKR1 Q8TCW9 1/20 0.37
CYP19A1 P11511 2/20 0.36
POLB P06746 1/20 0.35
PRKCZ Q05513 1/20 0.34
PKM P14618 1/20 0.34
ALOX12 P18054 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16610681 1.00 ALDH1A1 (0.39) ALDH1A1MAOAMAOBROCK2MEN1
SCHEMBL16610752 0.86 CYP19A1 (0.40) MAOAMAOBMAPTMAPK1CYP19A1
SCHEMBL16610830 0.84 POLB (0.39) ALDH1A1MAOAMAOBROCK2MEN1
SCHEMBL16610660 0.82 CYP19A1 (0.36) ALDH1A1MAOAMAOBMEN1KMT2A
SCHEMBL16610540 0.78 MAOA (0.35) ALDH1A1MAOAMAOBROCK2MEN1
SCHEMBL16610525 0.75 CYP19A1 (0.40) MEN1KMT2AMAPTMAPK1CYP19A1
SCHEMBL16610566 0.75 DRD2 (0.39) ALDH1A1ROCK2POLB
SCHEMBL16610894 0.74 CYP19A1 (0.34) ALDH1A1ROCK2MEN1KMT2ACYP19A1
SCHEMBL16610582 0.73 DRD2 (0.37) ALDH1A1ROCK2
SCHEMBL16610537 0.71 PRLHR (0.41) KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170143722-A1 SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS NIPPON SHINYAKU CO., LTD. (JP) 2017-05-25 US disclosed
US-9580413-B2 Substituted pyrrolidines as ROS tyrosine kinase inhibitors NIPPON SHINYAKU CO., LTD. (JP) 2017-02-28 US disclosed
US-20150152095-A1 AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL NIPPON SHINYAKU CO., LTD. (JP) 2015-06-04 US disclosed
EP-2857398-A1 AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL Nippon Shinyaku Co., Ltd. (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152095-A1 AROMATIC HETEROCYCLIC DERIVATIVE AND PHARMACEUTICAL HRH4, CYP3A4, CYP3A5 ALDH1A1 1015/4885MAOA 738/4885MAOB 893/4885
US-20170143722-A1 SUBSTITUTED PYRROLIDINES AS ROS TYROSINE KINASE INHIBITORS ROS1, NOX4, NOX3 ALDH1A1 1052/4885MAOA 1404/4885MAOB 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.